The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.
David Shultz
No relevant relationships to disclose
Jonathan Pai
No relevant relationships to disclose
Madeline Sydney Graber
No relevant relationships to disclose
Gregory M. Heestand
No relevant relationships to disclose
Daniel Tandel Chang
No relevant relationships to disclose
Wendy R. Parulekar
No relevant relationships to disclose
Dongsheng Tu
No relevant relationships to disclose
Malcolm J. Moore
No relevant relationships to disclose
Albert Koong
No relevant relationships to disclose